Contribution of antibody hydrodynamic size to vitreal clearance revealed through rabbit studies using a species-matched fab

Molecular Pharmaceutics

Volumn 13, Issue 9, 2016, Pages 2996-3003

  Shatz, Whitney ^a   Hass, Philip E ^a   Mathieu, Mary ^a   Kim, Hok Seon ^a   Leach, Kim ^a   Zhou, Michelle ^a   Crawford, Yongping ^a   Shen, Amy ^a   Wang, Kathryn ^a   Chang, Debby P ^a   Maia, Mauricio ^a   Crowell, Susan R ^a   Dickmann, Leslie ^a   Scheer, Justin M ^a   Kelley, Robert F ^a  

^a GENENTECH INC   (United States)

Author keywords

hydrodynamic radius; long acting delivery; ocular pharmacokinetics; PEGylation

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PEGAPTANIB; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; DRUG CLEARANCE; DRUG HALF LIFE; HYDRODYNAMICS; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RABBIT; SINGLE DRUG DOSE; STOP CODON; VITREOUS BODY; ANIMAL; CHEMISTRY; CHO CELL LINE; CRICETULUS; ENZYME LINKED IMMUNOSORBENT ASSAY; INTRAVITREAL DRUG ADMINISTRATION; KINETICS; LEPORIDAE; METABOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL; CHO CELLS; CRICETULUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HYDRODYNAMICS; IMMUNOGLOBULIN FAB FRAGMENTS; INTRAVITREAL INJECTIONS; KINETICS; POLYETHYLENE GLYCOLS; RABBITS;

EID: 84986253659     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.6b00345     Document Type: Article

References (35)

1. Busbee, B. G.; Ho, A. C.; Brown, D. M.; Heier, J. S.; Suner, I. J.; Li, Z.; Rubio, R. G.; Lai, P. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration Ophthalmology 2013, 120 (5) 1046-56 10.1016/j.ophtha.2012.10.014
2. Campochiaro, P. A.; Heier, J. S.; Feiner, L.; Gray, S.; Saroj, N.; Rundle, A. C.; Murahashi, W. Y.; Rubio, R. G. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study Ophthalmology 2010, 117 (6) 1102-1112 10.1016/j.ophtha.2010.02.021
3. Nguyen, Q. D.; Brown, D. M.; Marcus, D. M.; Boyer, D. S.; Patel, S.; Feiner, L.; Gibson, A.; Sy, J.; Rundle, A. C.; Hopkins, J. J.; Rubio, R. G.; Ehrlich, J. S. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE Ophthalmology 2012, 119 (4) 789-801 10.1016/j.ophtha.2011.12.039
4. Xu, L.; Lu, T.; Tuomi, L.; Jumbe, N.; Lu, J.; Eppler, S.; Kuebler, P.; Damico-Beyer, L. A.; Joshi, A. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach Invest. Ophthalmol. Visual Sci. 2013, 54 (3) 1616-24 10.1167/iovs.12-10260
5. Short, B. G. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations Toxicol. Pathol. 2008, 36 (1) 49-62 10.1177/0192623307310955
6. Del Amo, E. M.; Urtti, A. Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data Exp. Eye Res. 2015, 137, 111-24 10.1016/j.exer.2015.05.003
7. Gaudreault, J.; Fei, D.; Beyer, J. C.; Ryan, A.; Rangell, L.; Shiu, V.; Damico, L. A. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits Retina 2007, 27 (9) 1260-6 10.1097/IAE.0b013e318134eecd
8. Arai, H.; Glabe, C.; Luecke, H. Crystal structure of a conformation-dependent rabbit IgG Fab specific for amyloid prefibrillar oligomers Biochim. Biophys. Acta, Gen. Subj. 2012, 1820 (12) 1908-14 10.1016/j.bbagen.2012.08.016
9. del Amo, E. M.; Vellonen, K. S.; Kidron, H.; Urtti, A. Intravitreal clearance and volume of distribution of compounds in rabbits: In silico prediction and pharmacokinetic simulations for drug development Eur. J. Pharm. Biopharm. 2015, 95, 215-26 10.1016/j.ejpb.2015.01.003
10. Maurice, D. Review: practical issues in intravitreal drug delivery J. Ocul. Pharmacol. Ther. 2001, 17 (4) 393-401 10.1089/108076801753162807
11. Durairaj, C.; Shah, J. C.; Senapati, S.; Kompella, U. B. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR) Pharm. Res. 2009, 26 (5) 1236-60 10.1007/s11095-008-9728-7
12. Crawford, Y.; Zhou, M.; Hu, Z.; Joly, J.; Snedecor, B.; Shen, A.; Gao, A. Fast identification of reliable hosts for targeted cell line development from a limited-genome screening using combined phiC31 integrase and CRE-Lox technologies Biotechnology progress 2013, 29 (5) 1307-15 10.1002/btpr.1783
13. Zimm, B. H. The scattering of light and the radial distribution function of high polymer solutions J. Chem. Phys. 1948, 16 (12) 1093 10.1063/1.1746738
14. Wyatt, P. J. Light scattering and the absolute characterization of macromolecules Anal. Chim. Acta 1993, 272, 1 10.1016/0003-2670(93)80373-S
15. O'Donnell, I. J.; Frangione, B.; Porter, R. R. The disulphide bonds of the heavy chain of rabbit immunoglobulin G Biochem. J. 1970, 116 (2) 261-8 10.1042/bj1160261
16. Wakankar, A. A.; Borchardt, R. T. Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization J. Pharm. Sci. 2006, 95 (11) 2321-36 10.1002/jps.20740
17. Walls, G. L. The Vertebrate Eye and Its Adaptive Radiation; Hafner Publishing Company: New York, 1963.
18. Gadkar, K.; Pastuskovas, C. V.; Le Couter, J. E.; Elliott, J. M.; Zhang, J.; Lee, C. V.; Sanowar, S.; Fuh, G.; Kim, H. S.; Lombana, T. N.; Spiess, C.; Nakamura, M.; Hass, P.; Shatz, W.; Meng, Y. G.; Scheer, J. M. Design and Pharmacokinetic Characterization of Novel Antibody Formats for Ocular Therapeutics Invest. Ophthalmol. Visual Sci. 2015, 56 (9) 5390-400 10.1167/iovs.15-17108
19. Bailon, P.; Won, C. Y. PEG-modified biopharmaceuticals Expert Opin. Drug Delivery 2009, 6 (1) 1-16 10.1517/17425240802650568
20. Chapman, A. P.; Antoniw, P.; Spitali, M.; West, S.; Stephens, S.; King, D. J. Therapeutic antibody fragments with prolonged in vivo half-lives Nat. Biotechnol. 1999, 17 (8) 780-3 10.1038/11717
21. Chapman, A. P. PEGylated antibodies and antibody fragments for improved therapy: a review Adv. Drug Delivery Rev. 2002, 54 (4) 531-45 10.1016/S0169-409X(02)00026-1
22. Laurent, U. B.; Fraser, J. R. Turnover of hyaluronate in the aqueous humour and vitreous body of the rabbit Exp. Eye Res. 1983, 36 (4) 493-503 10.1016/0014-4835(83)90043-X
23. Maurice, D. M. Protein dynamics in the eye studied with labelled proteins Am. J. Ophthalmol. 1959, 47, 361-8 10.1016/S0002-9394(14)78042-0
24. Christoforidis, J. B.; Williams, M. M.; Kothandaraman, S.; Kumar, K.; Epitropoulos, F. J.; Knopp, M. V. Pharmacokinetic properties of intravitreal I-124-aflibercept in a rabbit model using PET/CT Curr. Eye Res. 2012, 37 (12) 1171-4 10.3109/02713683.2012.727521
25. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration Retina 2002, 22 (2) 143-52
26. Bakri, S. J.; Snyder, M. R.; Reid, J. M.; Pulido, J. S.; Singh, R. J. Pharmacokinetics of intravitreal bevacizumab (Avastin) Ophthalmology 2007, 114 (5) 855-9 10.1016/j.ophtha.2007.01.017
27. Xu, Q.; Boylan, N. J.; Suk, J. S.; Wang, Y. Y.; Nance, E. A.; Yang, J. C.; McDonnell, P. J.; Cone, R. A.; Duh, E. J.; Hanes, J. Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo J. Controlled Release 2013, 167 (1) 76-84 10.1016/j.jconrel.2013.01.018
28. Park, J.; Bungay, P. M.; Lutz, R. J.; Augsburger, J. J.; Millard, R. W.; Sinha Roy, A.; Banerjee, R. K. Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant J. Controlled Release 2005, 105 (3) 279-95 10.1016/j.jconrel.2005.03.010
29. Missel, P. J. Simulating intravitreal injections in anatomically accurate models for rabbit, monkey, and human eyes Pharm. Res. 2012, 29 (12) 3251-72 10.1007/s11095-012-0721-9
30. Hutton-Smith, L. A.; Gaffney, E. A.; Byrne, H. M.; Maini, P. K.; Schwab, D.; Mazer, N. A. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration Mol. Pharmaceutics 2016, 10.1021/acs.molpharmaceut.5b00849
31. Crank, J. The Mathematics of Diffusion; Oxford University Press: London, 1975; p 96.
32. Sebag, J. The Vitreous: Structure, Function, and Pathbiology; Springer-Verlag: New York, 1989.
33. Krohne, T. U.; Liu, Z.; Holz, F. G.; Meyer, C. H. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans Am. J. Ophthalmol. 2012, 154 (4) 682-686 10.1016/j.ajo.2012.03.047
34. Krohne, T. U.; Eter, N.; Holz, F. G.; Meyer, C. H. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans Am. J. Ophthalmol. 2008, 146 (4) 508-12 10.1016/j.ajo.2008.05.036
35. Apte, R. S.; Modi, M.; Masonson, H.; Patel, M.; Whitfield, L.; Adamis, A. P. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration Ophthalmology 2007, 114 (9) 1702-12 10.1016/j.ophtha.2007.02.021